{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:52:51Z","timestamp":1761519171333},"publisher-location":"Cham","reference-count":177,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319442501"},{"type":"electronic","value":"9783319442518"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/5584_2016_169","type":"book-chapter","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T08:56:10Z","timestamp":1479459370000},"page":"37-59","source":"Crossref","is-referenced-by-count":8,"title":["Pathophysiological Mechanisms and Correlates of Therapeutic Pharmacological Interventions in Essential Arterial Hypertension"],"prefix":"10.1007","author":[{"given":"Francesco","family":"Maranta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Spoladore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Fragasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"169_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejheart.2006.05.002","volume":"9","author":"J Abdulla","year":"2007","unstructured":"Abdulla J, Barlera S, Latini R et al (2007) A systematic review: effect of angiotensin converting enzyme-inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 9:129\u2013135","journal-title":"Eur J Heart Fail"},{"key":"169_CR2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.metabol.2007.06.012","volume":"56","author":"TA Aksnes","year":"2007","unstructured":"Aksnes TA, Seljeflot I, Torjesen PA et al (2007) Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 56:1470\u20131477","journal-title":"Metabolism"},{"key":"169_CR3","doi-asserted-by":"publisher","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283:1967\u20131975","DOI":"10.1001\/jama.283.15.1967"},{"key":"169_CR4","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981\u20132997","journal-title":"JAMA"},{"key":"169_CR177","doi-asserted-by":"publisher","unstructured":"Ames RP (1996) A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 77:12b\u201316b","DOI":"10.1016\/S0002-9149(97)89233-8"},{"key":"169_CR5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.amjcard.2006.10.068","volume":"99","author":"R Andraws","year":"2007","unstructured":"Andraws R, Brown DL (2007) Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99:1006\u20131012","journal-title":"Am J Cardiol"},{"key":"169_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1161\/01.HYP.1.3.274","volume":"1","author":"SA Atlas","year":"1979","unstructured":"Atlas SA, Case DB, Sealey JE et al (1979) Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1:274\u2013280","journal-title":"Hypertension"},{"key":"169_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/HYPERTENSIONAHA.111.189589","volume":"59","author":"K Ayers","year":"2012","unstructured":"Ayers K et al (2012) Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59:893\u2013898","journal-title":"Hypertension"},{"key":"169_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.hjh.0000202812.72341.99","volume":"24","author":"M Azizi","year":"2006","unstructured":"Azizi M et al (2006) Renin inhibition with aliskiren. where are we now, and where are we going. J Hypertens 24:243\u2013256","journal-title":"J Hypertens"},{"key":"169_CR9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/ki.1996.480","volume":"50","author":"GL Bakris","year":"1996","unstructured":"Bakris GL, Copley JB, Vicknair N et al (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641\u20131650","journal-title":"Kidney Int"},{"key":"169_CR10","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1046\/j.1523-1755.1998.00083.x","volume":"54","author":"GL Bakris","year":"1998","unstructured":"Bakris GL, Weir MR, DeQuattro V et al (1998) Effects of an ACE inhibitor\/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54:1283\u20131289","journal-title":"Kidney Int"},{"key":"169_CR11","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","volume":"292","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Fonseca V, Katholi RE et al (2004a) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227\u20132236","journal-title":"JAMA"},{"key":"169_CR12","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","volume":"65","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Weir MR, Secic M et al (2004b) Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65:1991\u20132002","journal-title":"Kidney Int"},{"key":"169_CR13","first-page":"229","volume":"32","author":"P Balansard","year":"1977","unstructured":"Balansard P, Chabrillat Y, Paulin R et al (1977) Effect of atenolol, a new cardioselective beta- blocker, on plasma renin activity in treatment of hypertension. Acta Cardiol 32:229\u2013243","journal-title":"Acta Cardiol"},{"key":"169_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1567201811310010011","volume":"10","author":"JL Balligand","year":"2013","unstructured":"Balligand JL (2013) Beta3-adrenoreceptors in cardiovasular diseases: new roles for an \u201cold\u201d receptor. Curr Drug Deliv 10:64\u201366","journal-title":"Curr Drug Deliv"},{"key":"169_CR15","doi-asserted-by":"publisher","first-page":"d22","DOI":"10.1136\/bmj.d2234","volume":"342","author":"S Bangalore","year":"2011","unstructured":"Bangalore S et al (2011) Angiotensin receptor blockers and risk of myocardial infarction. Meta-analyses and trial sequential analyses of 147,020 patients from randomised trials. BMJ 342:d22\u2013d34","journal-title":"BMJ"},{"key":"169_CR16","doi-asserted-by":"publisher","unstructured":"Beckett N, et al.: for the HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887\u20131898","DOI":"10.1056\/NEJMoa0801369"},{"key":"169_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/cpt1977225part1499","volume":"22","author":"WM Bennett","year":"1977","unstructured":"Bennett WM, McDonald WJ, Kuehnel E et al (1977) Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 22:499\u2013504","journal-title":"Clin Pharmacol Ther"},{"key":"169_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","volume":"165","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2005","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165:1410\u20131419","journal-title":"Arch Intern Med"},{"key":"169_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","volume":"25","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2007","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration (2007) Blood pressure-dependent and independent effects of agents that inhibit the renin angiotensin system. J Hypertens 25:951\u2013958","journal-title":"J Hypertens"},{"key":"169_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1161\/01.HYP.8.3.181","volume":"8","author":"HG Bohlen","year":"1986","unstructured":"Bohlen HG (1986) Localization of vascular resistance changes during hypertension. Hypertension 8:181\u2013183","journal-title":"Hypertension"},{"key":"169_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/S0002-9149(96)00816-8","volume":"79","author":"D Bonadue","year":"1997","unstructured":"Bonadue D, Petretta M, Ianniciello A et al (1997) Comparison of verapamil versus felodipine on heart rate variability after acute myocardial infarction. Am J Cardiol 79:564\u2013569","journal-title":"Am J Cardiol"},{"key":"169_CR22","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1097\/01.hjh.0000249685.58370.28","volume":"24","author":"HA Bradley","year":"2006","unstructured":"Bradley HA, Wiysonge CS, Volmink JA et al (2006) How strong is the evidence for use of beta- blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 24:2131\u20132141","journal-title":"J Hypertens"},{"key":"169_CR23","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJM198212233072605","volume":"307","author":"E Braunwald","year":"1982","unstructured":"Braunwald E (1982) Mechanism of action of calcium-channel-blocking agents. N Engl J Med 307:1618\u20131627","journal-title":"N Engl J Med"},{"key":"169_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1254\/jphs.CRJ06001X","volume":"100","author":"OE Brodde","year":"2006","unstructured":"Brodde OE et al (2006) Cardiac adrenoceptors. physiological and pathophysiological relevance. J Pharmacol Sci 100:323\u2013337","journal-title":"J Pharmacol Sci"},{"key":"169_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","volume":"377","author":"MJ Brown","year":"2011","unstructured":"Brown MJ et al (2011) Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 377:312\u2013320","journal-title":"Lancet"},{"key":"169_CR26","first-page":"99","volume":"32","author":"HR Brunner","year":"1973","unstructured":"Brunner HR, Sealey JE, Laragh JH (1973) Renin subgroups in essential hypertension. Further analysis of their pathophysiological and epidemiological characteristics. Circ Res 32:99\u2013105","journal-title":"Circ Res"},{"key":"169_CR27","doi-asserted-by":"publisher","first-page":"G28","DOI":"10.1093\/eurheartj\/13.suppl_G.28","volume":"13","author":"M Burnier","year":"1992","unstructured":"Burnier M, Brunner HR (1992) Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 13:G28\u2013G33","journal-title":"Eur Heart J"},{"key":"169_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"355","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355:637\u2013645","journal-title":"Lancet"},{"key":"169_CR29","doi-asserted-by":"publisher","unstructured":"Carter BL, Einhorn PT, Brands M, et al.; Working Group from the National Heart, Lung, and Blood Institute (2008) Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension 52:30\u201336","DOI":"10.1161\/HYPERTENSIONAHA.108.114389"},{"key":"169_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1517\/14728221003709784","volume":"14","author":"P Castro-Chaves","year":"2010","unstructured":"Castro-Chaves P, Cerqueira R, Pintalhao M et al (2010) New pathways of the renin\u2013angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. Export Opin Ther Targets 14:485\u2013496","journal-title":"Export Opin Ther Targets"},{"key":"169_CR31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/01.hjh.0000209993.26057.de","volume":"24","author":"T Celik","year":"2006","unstructured":"Celik T, Iyisoy A, Kursaklioglu H et al (2006) Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24:591\u2013596","journal-title":"J Hypertens"},{"key":"169_CR32","first-page":"S3","volume":"24","author":"C Chang","year":"2006","unstructured":"Chang C et al (2006) The effect on blood pressure and lipid profiles of doxazosin GITS as a third-line antihypertensive agent in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hypertens 24:S3","journal-title":"J Hypertens"},{"key":"169_CR33","first-page":"241","volume":"4","author":"MC Chellingsworth","year":"1990","unstructured":"Chellingsworth MC, Kendall MJ, Lote CJ et al (1990) Diuresis and natriuresis after dihydropyridines: role of prostaglandin E. J Hum Hypertens 4:241\u2013245","journal-title":"J Hum Hypertens"},{"issue":"4","key":"169_CR34","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3892\/mmr.2013.1329","volume":"7","author":"J Chen","year":"2013","unstructured":"Chen J et al (2013) The effects of carvedilol on cardiac structural remodeling: the role of endogenous nitric oxide in the activity of carvedilol. Mol Med Rep 7(4):1155\u20131158","journal-title":"Mol Med Rep"},{"key":"169_CR35","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR et al (2003) Seventh report of the Joint National Committee on prevention, detection evaluation, and treatment of high blood pressure. Hypertension 42:1206\u20131252","journal-title":"Hypertension"},{"key":"169_CR36","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJM198606263142602","volume":"314","author":"SH Croog","year":"1986","unstructured":"Croog SH, Levine S, Testa MA et al (1986) The effects of antihypertensive therapy on the quality of life. N Engl J Med 314:1657\u20131664","journal-title":"N Engl J Med"},{"key":"169_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/HJH.0b013e32834000be","volume":"29","author":"S Czernichow","year":"2011","unstructured":"Czernichow S, Blood Pressure Lowering Treatment Trialists\u2019 Collaboration et al (2011) The effects of blood pressure reduction and different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressuremeta-analysis of randomized trials. J Hypertens 29:4\u201316","journal-title":"J Hypertens"},{"key":"169_CR38","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","volume":"28","author":"K Dahal","year":"2015","unstructured":"Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP (2015) The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens 28:1376\u20131385","journal-title":"Am J Hypertens"},{"key":"169_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dalh\u00f6f","year":"2005","unstructured":"Dalh\u00f6f B et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). A multicentre randomised controlled trial. Lancet 366:895\u2013906","journal-title":"Lancet"},{"key":"169_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","volume":"9","author":"BR Davis","year":"1996","unstructured":"Davis BR, Cutler JA, Gordon DJ et al (1996) Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Research Group. Am J Hypertens 9:342\u2013360","journal-title":"Am J Hypertens"},{"key":"169_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ejphar.2005.04.004","volume":"516","author":"CV Gennaro De","year":"2005","unstructured":"De Gennaro CV, Rigamonti A et al (2005) Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L- NAME-induced hypertensive rats. Eur J Pharmacol 516:253\u2013259","journal-title":"Eur J Pharmacol"},{"key":"169_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1751-7176.2011.00564.x","volume":"14","author":"B Dussol","year":"2012","unstructured":"Dussol B et al (2012) A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens 14:32\u201337","journal-title":"J Clin Hypertens"},{"key":"169_CR43","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/00004872-198912000-00001","volume":"7","author":"VJ Dzau","year":"1989","unstructured":"Dzau VJ (1989) Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 7:933\u2013936","journal-title":"J Hypertens"},{"key":"169_CR44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/BF00615401","volume":"20","author":"K Eliasson","year":"1981","unstructured":"Eliasson K, Lins LE, R\u00f6ssner S (1981) Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 20:335\u2013338","journal-title":"Eur J Clin Pharmacol"},{"key":"169_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2125.1985.tb02665.x","volume":"19","author":"MD Ene","year":"1985","unstructured":"Ene MD, Williamson PJ, Roberts CJC et al (1985) The natriuresis following oral administration of the calcium antagonists-nifedipine and nitrendipine. Br J Clin Pharmacol 19:423\u2013427","journal-title":"Br J Clin Pharmacol"},{"key":"169_CR46","first-page":"349","volume-title":"Calcium antagonists in clinical medicine","author":"M Epstein","year":"1992","unstructured":"Epstein M, De Micheli AG (1992) Natriuretic effects of calcium antagonists. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 349\u2013366"},{"key":"169_CR47","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1161\/HYPERTENSIONAHA.108.119404","volume":"52","author":"JW Eriksson","year":"2008","unstructured":"Eriksson JW, Jansson PA, Carlberg B et al (2008) Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 52:1030\u20131037","journal-title":"Hypertension"},{"key":"169_CR48","first-page":"215s","volume":"3","author":"R Fagard","year":"1976","unstructured":"Fagard R, Amery A, Deplaen JF et al (1976) Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol. Clin Sci Mol Med Suppl 3:215s\u2013217s","journal-title":"Clin Sci Mol Med Suppl"},{"key":"169_CR49","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","volume":"54","author":"RH Fagard","year":"2009","unstructured":"Fagard RH, Celis H, Thijs L, Wouters S (2009) Regression of left ventricular mass by anti-hypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 54:1084\u20131091","journal-title":"Hypertension"},{"key":"169_CR50","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1056\/NEJM198708063170605","volume":"317","author":"E Ferrannini","year":"1987","unstructured":"Ferrannini E, Buzzigoli G, Bonadonna R et al (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350\u2013357","journal-title":"N Engl J Med"},{"key":"169_CR51","doi-asserted-by":"publisher","first-page":"26B","DOI":"10.1016\/0002-9149(91)90817-5","volume":"67","author":"P Ferrari","year":"1991","unstructured":"Ferrari P, Rosman J, Weidmann P (1991) Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 67:26B\u201335B","journal-title":"Am J Cardiol"},{"key":"169_CR52","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/HJH.0b013e3280287a72","volume":"25","author":"AJ Flammer","year":"2007","unstructured":"Flammer AJ, Hermann F, Wiesli P et al (2007) Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 25:785\u2013791","journal-title":"J Hypertens"},{"key":"169_CR53","first-page":"125","volume":"3","author":"AE Fletcher","year":"1989","unstructured":"Fletcher AE, Chester PC, Hawkins CM et al (1989) The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 3:125\u2013130","journal-title":"J Hum Hypertens"},{"key":"169_CR54","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1046\/j.1440-1681.2003.03911.x","volume":"30","author":"FA Fonseca","year":"2003","unstructured":"Fonseca FA, Ihara SS, Izar MC et al (2003) Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril. Clin Exp Pharmacol Physiol 30:779\u2013785","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"169_CR55","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782\u2013788","journal-title":"Lancet"},{"key":"169_CR56","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.jacc.2008.12.075","volume":"53","author":"G Fragasso","year":"2009","unstructured":"Fragasso G, Cera M, Margonato A (2009) Different metabolic effects of selective and non- selective beta-blockers rather than mere heart rate reduction may be the mechanism by which beta- blockade prevents cardiovascular events. J Am Coll Cardiol 53:2105","journal-title":"J Am Coll Cardiol"},{"key":"169_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1517\/14728222.2012.655724","volume":"16","author":"G Fragasso","year":"2012","unstructured":"Fragasso G, Maranta F, Montanaro C, Salerno A, Torlasco C, Margonato A (2012) Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. Expert Opin Ther Targets 16:179\u2013193","journal-title":"Expert Opin Ther Targets"},{"key":"169_CR58","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/00004872-200018080-00021","volume":"18","author":"LV Franse","year":"2000","unstructured":"Franse LV, Pahor M, Di Bari M et al (2000) Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 18:1149\u20131154","journal-title":"J Hypertens"},{"key":"169_CR59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0002-8703(83)90116-3","volume":"106","author":"ED Freis","year":"1983","unstructured":"Freis ED (1983) How diuretics lower blood pressure. Am Heart J 106:185\u2013187","journal-title":"Am Heart J"},{"key":"169_CR60","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1161\/01.CIR.92.5.1326","volume":"92","author":"CD Furberg","year":"1995","unstructured":"Furberg CD, Psaty BM, Meyer JV (1995) Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326\u20131331","journal-title":"Circulation"},{"key":"169_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/BF00541924","volume":"26","author":"JF Giudicelli","year":"1984","unstructured":"Giudicelli JF, Berdeaux A, Edouard A et al (1984) Attenuation by diltiazem of arterial baroreflex sensitivity in man. Eur J Clin Pharmacol 26:675\u2013679","journal-title":"Eur J Clin Pharmacol"},{"key":"169_CR62","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/BF00051108","volume":"10","author":"D Godfraind","year":"1996","unstructured":"Godfraind D, Salomone S (1996) Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc Drugs Ther 10:439\u2013446","journal-title":"Cardiovasc Drugs Ther"},{"key":"169_CR63","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1097\/00004872-200309000-00027","volume":"21","author":"G Grassi","year":"2003","unstructured":"Grassi G, Seravalle G, Dell\u2019Oro R et al (2003) Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 21:1761\u20131769","journal-title":"J Hypertens"},{"key":"169_CR64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.HYP.29.1.8","volume":"29","author":"RH Grimm","year":"1997","unstructured":"Grimm RH et al (1997) Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 29:8\u201314","journal-title":"Hypertension"},{"key":"169_CR65","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2337\/dc07-1768","volume":"31","author":"AK Gupta","year":"2008","unstructured":"Gupta AK, Dahlof B, Dobson J et al (2008) Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 31:982\u2013988","journal-title":"Diabetes Care"},{"key":"169_CR66","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00004872-199816010-00016","volume":"16","author":"T Hamada","year":"1998","unstructured":"Hamada T, Watanabe M, Kaneda T et al (1998) Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 16:111\u2013118","journal-title":"J Hypertens"},{"key":"169_CR67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","volume":"309","author":"T Hannedouche","year":"1994","unstructured":"Hannedouche T, Landais P, Goldfarb B et al (1994) Randomised controlled trial of enalapril and \u03b2 blockers in non-diabetic chronic renal failure. BMJ 309:833\u2013837","journal-title":"BMJ"},{"key":"169_CR68","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"HOPE (Heart Outcomes Prevention Evaluation) Study Investigators","year":"2000","unstructured":"HOPE (Heart Outcomes Prevention Evaluation) Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145\u2013153","journal-title":"N Engl J Med"},{"key":"169_CR69","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0002-8703(93)90208-Q","volume":"125","author":"S Huang","year":"1993","unstructured":"Huang S, Simonson MS, Dunn MJ (1993) Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin\u2019s effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J 125:589\u2013597","journal-title":"Am Heart J"},{"key":"169_CR70","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.yjmcc.2007.07.047","volume":"43","author":"BS Huang","year":"2007","unstructured":"Huang BS, Ahmad M, Tan J et al (2007) Sympathetic hyperactivity and cardiac dysfunction post- MI: different impact of specific CNS versus general AT1 receptor blockade. J Mol Cell Cardiol 43:479\u2013486","journal-title":"J Mol Cell Cardiol"},{"key":"169_CR71","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/0002-9149(82)90381-2","volume":"49","author":"Y Imai","year":"1982","unstructured":"Imai Y, Abe K, Seino M et al (1982) Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II. Am J Cardiol 49:1537\u20131539","journal-title":"Am J Cardiol"},{"key":"169_CR72","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/0024-3205(84)90013-4","volume":"34","author":"PA Insel","year":"1984","unstructured":"Insel PA, Motulsky HJ (1984) A hypothesis linking intracellular sodium, membrane receptors, and hypertension. Life Sci 34:1009\u20131013","journal-title":"Life Sci"},{"key":"169_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2125.1983.tb02138.x","volume":"16","author":"T Ishizaki","year":"1983","unstructured":"Ishizaki T, Oyama Y, Suganuma T et al (1983) A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics. Br J Clin Pharmacol 16:17\u201325","journal-title":"Br J Clin Pharmacol"},{"key":"169_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","volume":"117","author":"ZH Israeli","year":"1992","unstructured":"Israeli ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin- converting enzyme inhibitor therapy; a review of the literature and pathophysiology. Ann Intern Med 117:234\u2013242","journal-title":"Ann Intern Med"},{"key":"169_CR75","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL et al (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417\u20132428","journal-title":"N Engl J Med"},{"key":"169_CR76","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL et al (2014) Evidence-based guideline for the management of high BP in adults. JAMA 311:507\u2013520","journal-title":"JAMA"},{"key":"169_CR77","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","volume":"49","author":"J Jordan","year":"2007","unstructured":"Jordan J et al (2007) Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 49:1047\u20131055","journal-title":"Hypertension"},{"key":"169_CR78","first-page":"13","volume":"62","author":"NK Kabra","year":"2014","unstructured":"Kabra NK (2014) Alpha blockers and metabolic syndrome. J Assoc Physicians India 62:13\u201316","journal-title":"J Assoc Physicians India"},{"key":"169_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/01.HYP.26.1.143","volume":"26","author":"MT Kailasam","year":"1995","unstructured":"Kailasam MT, Parmer RJ, Cervenka JH et al (1995) Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 26:143\u2013149","journal-title":"Hypertension"},{"key":"169_CR80","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1097\/01.hjh.0000234121.48272.67","volume":"24","author":"T Kaiser","year":"2006","unstructured":"Kaiser T, Heise T, Nosek L et al (2006) Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 24:1397\u20131403","journal-title":"J Hypertens"},{"key":"169_CR81","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","volume":"107","author":"L Kalinowski","year":"2003","unstructured":"Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al (2003) Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107:2747\u20132752","journal-title":"Circulation"},{"key":"169_CR82","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/HYPERTENSIONAHA.110.155507","volume":"57","author":"P Kampus","year":"2011","unstructured":"Kampus P et al (2011) Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 57:1122\u20131128","journal-title":"Hypertension"},{"key":"169_CR83","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jama.1989.03430060113035","volume":"262","author":"NM Kaplan","year":"1989","unstructured":"Kaplan NM (1989) Calcium entry blockers in the treatment of hypertension: current status and future prospects. JAMA 262:817\u2013823","journal-title":"JAMA"},{"key":"169_CR84","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/0003-4819-122-2-199501150-00010","volume":"122","author":"BL Kasiske","year":"1995","unstructured":"Kasiske BL et al (1995) Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122:133\u2013141","journal-title":"Ann Intern Med"},{"key":"169_CR85","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/00005344-198906147-00003","volume":"14","author":"MJ Kendall","year":"1989","unstructured":"Kendall MJ (1989) Pharmacology of third generation beta blockers: greater benefits, fewer risks. J Cardiovasc Pharmacol 14:S4\u2013S8","journal-title":"J Cardiovasc Pharmacol"},{"key":"169_CR86","first-page":"1","volume":"43","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI)","year":"2004","unstructured":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) (2004) K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43:1\u2013290","journal-title":"Am J Kidney Dis"},{"key":"169_CR87","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1475-2840-6-12","volume":"6","author":"U Kintscher","year":"2007","unstructured":"Kintscher U, Bramlage P, Paar WD et al (2007) Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a subanalysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 6:12","journal-title":"Cardiovasc Diabetol"},{"key":"169_CR88","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1046\/j.1523-1755.1998.00912.x","volume":"53","author":"HJ Kloke","year":"1998","unstructured":"Kloke HJ, Branten AJ, Huysmans FT et al (1998) Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 53:1559\u20131573","journal-title":"Kidney Int"},{"key":"169_CR89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","volume":"95","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, Wilson AC, Freudenberger RS, SHEP Collaborative Research Group et al (2005) Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29\u201335","journal-title":"Am J Cardiol"},{"key":"169_CR90","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1056\/NEJM199002013220502","volume":"322","author":"AZ LaCroix","year":"1990","unstructured":"LaCroix AZ et al (1990) Thiazide diuretic agents and the incidence of hip fracture. New Engl J Med 322:286\u2013290","journal-title":"New Engl J Med"},{"key":"169_CR91","first-page":"1409","volume-title":"Handblock of physiology","author":"JH Laragh","year":"1991","unstructured":"Laragh JH, Sealey JE (1991) Renin angiotensin aldosterone system and the renal regulation of sodium, potassium, and blood pressure homeostasis. In: Windhager EE (ed) Handblock of physiology. Renal physiology Oxford University Press, New York, pp 1409\u20131541"},{"key":"169_CR92","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665","journal-title":"BMJ"},{"key":"169_CR93","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"169_CR94","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","volume":"21","author":"LH Lindholm","year":"2003","unstructured":"Lindholm LH et al (2003) Metabolic outcome during 1 year in newly detected hypertensives. results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21:1563\u20131574","journal-title":"J Hypertens"},{"key":"169_CR95","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","volume":"366","author":"LH Lindholm","year":"2005","unstructured":"Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545\u20131553","journal-title":"Lancet"},{"key":"169_CR96","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2337\/diacare.14.3.203","volume":"14","author":"HO Lithell","year":"1991","unstructured":"Lithell HO (1991) Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14:203\u2013209","journal-title":"Diabetes Care"},{"key":"169_CR97","first-page":"F619","volume":"249","author":"R Loutzenhiser","year":"1985","unstructured":"Loutzenhiser R, Epstein M (1985) Effects of calcium antagonists on renal hemodynamics. Am J Physiol 249:F619\u2013F629","journal-title":"Am J Physiol"},{"key":"169_CR98","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00005344-198705000-00005","volume":"9","author":"P Madeddu","year":"1987","unstructured":"Madeddu P, Oppes M, Soro A et al (1987) Natriuretic effect of acute nifedipine administration is not mediated by the renal kallikrein-kinin system. J Cardiovasc Pharmacol 9:536\u2013540","journal-title":"J Cardiovasc Pharmacol"},{"key":"169_CR99","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ajh\/1.1.91","volume":"1","author":"AJ Man in\u2019t Veld","year":"1988","unstructured":"Man in\u2019t Veld AJ, Van den Meiracker AH, Schalekamp MA (1988) Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1:91\u201396","journal-title":"Am J Hypertens"},{"key":"169_CR100","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1097\/01.hjh.0000220407.84363.fb","volume":"24","author":"G Mancia","year":"2006","unstructured":"Mancia G, Dell\u2019Oro R, Quarti-Trevano F et al (2006) Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl 24:S51\u2013S56","journal-title":"J Hypertens Suppl"},{"key":"169_CR101","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewica K et al (2013) 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34:2159\u20132219","journal-title":"Eur Heart J"},{"key":"169_CR102","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.1996.03530300007004","volume":"275","author":"C Marwick","year":"1996","unstructured":"Marwick C (1996) FDA gives calcium channel blockers clean bill of health but warns of short- acting nifedipine hazards. JAMA 275:423\u2013424","journal-title":"JAMA"},{"key":"169_CR103","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1161\/CIRCULATIONAHA.105.556233","volume":"112","author":"RP Mason","year":"2005","unstructured":"Mason RP, Kalinowski L, Jacob RF et al (2005) Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112:3795\u20133801","journal-title":"Circulation"},{"key":"169_CR104","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","volume":"148","author":"DB Matchar","year":"2008","unstructured":"Matchar DB et al (2008a) Systematic review. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148:16\u201329","journal-title":"Ann Intern Med"},{"key":"169_CR105","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","volume":"148","author":"DB Matchar","year":"2008","unstructured":"Matchar DB, McCrory DC, Orlando LA et al (2008b) Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148:16\u201329","journal-title":"Ann Intern Med"},{"key":"169_CR106","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387\u20132398","journal-title":"N Engl J Med"},{"key":"169_CR107","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart 33:1787\u20131847","journal-title":"Eur J Heart"},{"key":"169_CR108","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1378\/chest.45.4.360","volume":"45","author":"M Mendlowitz","year":"1964","unstructured":"Mendlowitz M, Gitlow SE, Wolf RL et al (1964) Mechanisms in essential hypertension. Dis Chest 45:360\u2013364","journal-title":"Dis Chest"},{"key":"169_CR109","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0735-1097(01)01534-0","volume":"38","author":"FH Messerli","year":"2001","unstructured":"Messerli FH (2001) Doxazosin and congestive heart failure. J Am Coll Cardiol 38:1295\u20131296","journal-title":"J Am Coll Cardiol"},{"key":"169_CR110","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","volume":"279","author":"FH Messerli","year":"1998","unstructured":"Messerli FH et al (1998) Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903\u20131907","journal-title":"JAMA"},{"key":"169_CR111","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0735-1097(02)01976-9","volume":"40","author":"MG Modena","year":"2002","unstructured":"Modena MG, Bonetti L, Coppi F et al (2002) Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40:505\u2013510","journal-title":"J Am Coll Cardiol"},{"key":"169_CR112","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.amjhyper.2003.09.012","volume":"17","author":"T Morgan","year":"2004","unstructured":"Morgan T, Lauri J, Bertram D et al (2004) Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 17:118\u2013123","journal-title":"Am J Hypertens"},{"key":"169_CR113","doi-asserted-by":"publisher","first-page":"44D","DOI":"10.1016\/0002-9149(86)90805-2","volume":"57","author":"G Muiesan","year":"1986","unstructured":"Muiesan G, Agabiti-Rosei E, Romanelli G et al (1986) Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 57:44D\u201349D","journal-title":"Am J Cardiol"},{"key":"169_CR114","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/01.HYP.0000184541.24700.c7","volume":"46","author":"S Nathan","year":"2005","unstructured":"Nathan S, Pepine CJ, Bakris GL (2005) Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 46:637\u2013642","journal-title":"Hypertension"},{"key":"169_CR115","unstructured":"National Institute for Health and Clinical Excellence. Hypertension (CG127). Web site http:\/\/www.nice.org.uk\/guidance\/cg127 . Accessed 2 Oct 2014."},{"key":"169_CR116","first-page":"9","volume":"62","author":"RP Nerurkar","year":"2014","unstructured":"Nerurkar RP, Ved JK (2014) Clinical pharmacology of alpha-1 blockers improving drug-profile through novel formulations. J Assoc Physicians India 62:9\u201312","journal-title":"J Assoc Physicians India"},{"key":"169_CR117","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","volume":"49","author":"BH Oh","year":"2007","unstructured":"Oh BH et al (2007) Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49:1157\u20131163","journal-title":"J Am Coll Cardiol"},{"key":"169_CR118","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0033-0620(96)80014-4","volume":"38","author":"LH Opie","year":"1996","unstructured":"Opie LH (1996) Calcium channel antagonists in the treatment of coronary artery disease. fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 38:273\u2013290","journal-title":"Prog Cardiovasc Dis"},{"key":"169_CR119","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1161\/01.CIR.92.5.1068","volume":"92","author":"LH Opie","year":"1995","unstructured":"Opie LH et al (1995) Nifedipine and mortality. grave defects in the dossier. Circulation 92:1068\u20131073","journal-title":"Circulation"},{"key":"169_CR120","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/01.CIR.87.5.1468","volume":"87","author":"JA Panza","year":"1993","unstructured":"Panza JA, Casino PR, Kilcoyne CM, Quyumi AA (1993) Role of nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87:1468\u20131474","journal-title":"Circulation"},{"key":"169_CR121","first-page":"175","volume":"6","author":"G Paolisso","year":"1992","unstructured":"Paolisso G, Gambardella A, Verza M et al (1992) ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6:175\u2013179","journal-title":"J Hum Hypertens"},{"key":"169_CR122","doi-asserted-by":"publisher","first-page":"114A","DOI":"10.1016\/S0895-7061(01)02110-0","volume":"14","author":"MV Papavassiliou","year":"2001","unstructured":"Papavassiliou MV, Vyssoulis GP, Karpanou EA et al (2001) Side effects of antihypertensive treatment with calcium channel antagonists. Am J Hypertens 14:114A","journal-title":"Am J Hypertens"},{"key":"169_CR123","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/00004872-200105000-00013","volume":"19","author":"JB Park","year":"2001","unstructured":"Park JB, Schiffrin EL (2001) Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 19:921\u2013930","journal-title":"J Hypertens"},{"key":"169_CR124","doi-asserted-by":"publisher","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204\u20132213","DOI":"10.1056\/NEJMoa1208799"},{"key":"169_CR125","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/ajh.2008.260","volume":"21","author":"AF Pasini","year":"2008","unstructured":"Pasini AF, Garbin U, Stranieri C et al (2008) Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 21:1251\u20131257","journal-title":"Am J Hypertens"},{"key":"169_CR126","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/eurheartj\/ehs014","volume":"34","author":"MA Pfeffer","year":"2013","unstructured":"Pfeffer MA (2013) Cancer in cardiovascular drug trials and vice versa. A personal perspective. Eur Heart J 34:1089\u20131094","journal-title":"Eur Heart J"},{"key":"169_CR127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.0954-6820.1979.tb13477.x","volume":"206","author":"T Pitk\u00e4j\u00e4rvi","year":"1979","unstructured":"Pitk\u00e4j\u00e4rvi T, Ylitalo P, Mets\u00e4-Ketel\u00e4 T et al (1979) The effects of a beta 1-blocking agent, atenolol, on blood pressure, plasma renin activity and prostaglandin F2 alpha excretion in patients with essential hypertension. Acta Med Scand 206:107\u2013113","journal-title":"Acta Med Scand"},{"key":"169_CR128","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"169_CR129","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033\u20131041","journal-title":"Lancet"},{"key":"169_CR130","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","volume":"277","author":"BM Psaty","year":"1997","unstructured":"Psaty BM, Smith NL, Siscovick DS et al (1997) Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277:739\u2013745","journal-title":"JAMA"},{"key":"169_CR131","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.amjcard.2010.08.023","volume":"106","author":"CV Ram","year":"2010","unstructured":"Ram CV (2010) Beta-blockers in hypertension. Am J Cardiol 106:1819\u20131825","journal-title":"Am J Cardiol"},{"issue":"Suppl 5","key":"169_CR132","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003495-199700545-00009","volume":"54","author":"WJ Remme","year":"1997","unstructured":"Remme WJ (1997) Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy? Drugs 54(Suppl 5):59\u201370","journal-title":"Drugs"},{"key":"169_CR133","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/MNH.0b013e328305b9a5","volume":"17","author":"S Reungjui","year":"2008","unstructured":"Reungjui S, Pratipanawatr T, Johnson RJ et al (2008) Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 17:470\u2013476","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"169_CR134","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0897190015615879","volume":"29","author":"TL Ripley","year":"2016","unstructured":"Ripley TL, Baumert M (2016) Controversies among the hypertension guidelines. J Pharm Pract 29:5\u201314","journal-title":"J Pharm Pract"},{"key":"169_CR135","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/107424840300800206","volume":"8","author":"E Rizos","year":"2003","unstructured":"Rizos E, Bairaktari E, Kostoula A et al (2003) The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 8:127\u2013134","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"169_CR136","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","volume":"9","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM et al (2010) Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9:469\u2013480","journal-title":"Lancet Neurol"},{"key":"169_CR137","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","volume":"34","author":"GC Roush","year":"2016","unstructured":"Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA (2016) Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens 34:11\u201319","journal-title":"J Hypertens"},{"key":"169_CR138","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/j.1476-5381.1995.tb14964.x","volume":"114","author":"S Salomone","year":"1995","unstructured":"Salomone S, Morel N, Godfraind T (1995) Effects of 8-bromocyclic GMP and verapamil on depolarization-evoked Ca 2+ signal and contraction in rat aorta. Br J Pharmacol 114:1731\u20131737","journal-title":"Br J Pharmacol"},{"key":"169_CR139","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/BF00168443","volume":"354","author":"S Salomone","year":"1996","unstructured":"Salomone S, Silva LM, Morel N et al (1996) Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch Pharmacol 354:505\u2013512","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"Suppl 1","key":"169_CR140","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/00003495-198500301-00008","volume":"30","author":"RA S\u00e1nchez","year":"1985","unstructured":"S\u00e1nchez RA, Marc\u00f3 E, Gilbert HB et al (1985) Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs 30(Suppl 1):49\u201358","journal-title":"Drugs"},{"key":"169_CR141","first-page":"129","volume":"11","author":"J Sasaki","year":"1989","unstructured":"Sasaki J, Arakawa K (1989) Effect of captopril on high-density lipoprotein subfractions in patients with mild to moderate essential hypertension. Clin Ther 11:129\u2013134","journal-title":"Clin Ther"},{"key":"169_CR142","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/00004872-199610000-00014","volume":"14","author":"LE Schiffrin","year":"1996","unstructured":"Schiffrin LE, Deng LY (1996) Structure and function of resistance arteries of hypertensive patients treated with a \u00df-blocker or a calcium channel antagonist. J Hypertens 14:1247\u20131255","journal-title":"J Hypertens"},{"key":"169_CR143","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/HYPERTENSIONAHA.108.119438","volume":"52","author":"T Shafi","year":"2008","unstructured":"Shafi T, Appel LJ, Miller ER 3rd et al (2008) Changes in serum potassium mediate thiazide- induced diabetes. Hypertension 52:1022\u20131029","journal-title":"Hypertension"},{"key":"169_CR144","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.amjcard.2010.02.031","volume":"106","author":"MC Shibata","year":"2010","unstructured":"Shibata MC, Le\u00f3n H, Chatterley T et al (2010) Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Am J Cardiol 106:228\u2013235","journal-title":"Am J Cardiol"},{"key":"169_CR145","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY et al (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11:627\u2013636","journal-title":"Lancet Oncol"},{"key":"169_CR146","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1046\/j.1523-1755.1998.00055.x","volume":"54","author":"AC Smith","year":"1998","unstructured":"Smith AC, Toto R, Bakris GL (1998) Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 54:889\u2013896","journal-title":"Kidney Int"},{"key":"169_CR147","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1440-1681.1987.tb00997.x","volume":"14","author":"J Staszewska-Woolley","year":"1987","unstructured":"Staszewska-Woolley J (1987) Modification by diltiazem, a calcium antagonist, of the pulmonary vagal and cardiac sympathetic chemoreflexes in the dog. Clin Exp Pharmacol Physiol 14:455\u2013464","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"169_CR148","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","volume":"114","author":"MH Strauss","year":"2006","unstructured":"Strauss MH et al (2006) Angiotensin receptor blockers may increase risk of myocardial infarction. Unraling the ARB-MI paradox. Circulation 114:838\u2013854","journal-title":"Circulation"},{"key":"169_CR149","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1161\/01.CIR.101.15.1848","volume":"101","author":"JB Su","year":"2000","unstructured":"Su JB, Ho\u00fcel R, H\u00e9loire F (2000) Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation. Circulation 101:1848\u20131853","journal-title":"Circulation"},{"key":"169_CR150","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1097\/00004872-200108000-00005","volume":"19","author":"S Taddei","year":"2001","unstructured":"Taddei S, Virdis A, Ghiadoni L et al (2001) Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 19:1379\u20131386","journal-title":"J Hypertens"},{"issue":"26","key":"169_CR151","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/eurheartj\/ehu079","volume":"35","author":"KK Teo","year":"2014","unstructured":"Teo KK et al (2014) Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J 35(26):1743\u20131751","journal-title":"Eur Heart J"},{"key":"169_CR152","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","volume":"4","author":"JM Testani","year":"2011","unstructured":"Testani JM, Kimmel SE, Dries DL et al (2011) Prognostic importance of early worsening renal function after initiation of Angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4:685\u2013691","journal-title":"Circ Heart Fail"},{"key":"169_CR153","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293\u2013302","journal-title":"N Engl J Med"},{"key":"169_CR154","doi-asserted-by":"publisher","unstructured":"TOMH Study, Neaton JD, et al. Treatment of Mild Hypertension study (TOMH) (1993) Final results. JAMA 270:713\u2013724","DOI":"10.1001\/jama.1993.03510060059034"},{"key":"169_CR155","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362:1527\u20131535","journal-title":"Lancet"},{"key":"169_CR156","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1023\/A:1007769800723","volume":"12","author":"M Vaage-Nilsen","year":"1998","unstructured":"Vaage-Nilsen M, Rasmussen V (1998) Effect of Verapamil on heart rate variability after an acute myocardial infarction. Cardiovasc Drugs Ther 12:285\u2013290","journal-title":"Cardiovasc Drugs Ther"},{"key":"169_CR157","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00129784-200808010-00005","volume":"8","author":"LM Bortel Van","year":"2008","unstructured":"Van Bortel LM, Fici F, Mascagni F (2008) Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 8:35\u201344","journal-title":"Am J Cardiovasc Drugs"},{"key":"169_CR158","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1161\/01.RES.53.3.389","volume":"53","author":"SF Vatner","year":"1983","unstructured":"Vatner SF, Hintze TH (1983) Mechanism of constriction of large coronary arteries by \u03b2- adrenergic receptor blockade. Circ Res 53:389\u2013400","journal-title":"Circ Res"},{"key":"169_CR159","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","volume":"46","author":"P Verdecchia","year":"2005","unstructured":"Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C (2005) Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46:386\u2013392","journal-title":"Hypertension"},{"key":"169_CR160","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1475-2840-4-6","volume":"4","author":"C Vitale","year":"2005","unstructured":"Vitale C, Mercuro G, Castiglioni C et al (2005) Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4:6","journal-title":"Cardiovasc Diabetol"},{"key":"169_CR161","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/ajh\/5.1.37","volume":"5","author":"S Wassertheil-Smoller","year":"1992","unstructured":"Wassertheil-Smoller S, Oberman A, Blaufox MD et al (1992) The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 5:37\u201344","journal-title":"Am J Hypertens"},{"key":"169_CR162","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1524-6175.2003.02287.x","volume":"5","author":"MA Weber","year":"2003","unstructured":"Weber MA (2003) The ALLHAT report: a case of information and misinformation. J Clin Hypertens 5:9\u201313","journal-title":"J Clin Hypertens"},{"key":"169_CR163","first-page":"322","volume":"5","author":"MA Weber","year":"2003","unstructured":"Weber MA, Bakris GL, Neutel JM et al (2003) Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens 5:322\u2013329","journal-title":"J Clin Hypertens"},{"key":"169_CR164","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","volume":"32","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB et al (2014) Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32:3\u201315","journal-title":"J Hypertens"},{"key":"169_CR165","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/BF01614293","volume":"54","author":"P Weidmann","year":"1976","unstructured":"Weidmann P, Beretta-Piccoli C, Ziegler W et al (1976) Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during beta-blockade in essential hypertension. Klin Wochenschr 54:765\u2013773","journal-title":"Klin Wochenschr"},{"key":"169_CR166","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1524-6175.2003.02216.x","volume":"5","author":"MR Weir","year":"2003","unstructured":"Weir MR (2003) Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens 5:330\u2013335","journal-title":"J Clin Hypertens"},{"key":"169_CR167","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","volume":"165","author":"P Whelton","year":"2005","unstructured":"Whelton P, Barzilay J, Cushman WC et al (2005) Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives Intern Med 165:1401\u20131409","journal-title":"Archives Intern Med"},{"key":"169_CR168","first-page":"557","volume":"19","author":"CS Wilcox","year":"1999","unstructured":"Wilcox CS (1999) Metabolic and adverse effects of diuretics. Semin Nephrol 19:557\u2013568","journal-title":"Semin Nephrol"},{"key":"169_CR169","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.606962","volume":"113","author":"B Williams","year":"2006","unstructured":"Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213\u20131225","journal-title":"Circulation"},{"key":"169_CR170","first-page":"CD002003","volume":"1","author":"CS Wiysonge","year":"2007","unstructured":"Wiysonge CS, Bradley H, Mayosi BM et al (2007) Beta-blockers for hypertension. Cochrane Database Syst Rev 1:CD002003","journal-title":"Cochrane Database Syst Rev"},{"key":"169_CR171","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T et al (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421\u20132431","journal-title":"JAMA"},{"key":"169_CR172","doi-asserted-by":"publisher","unstructured":"Yusuf S, Teo KK, Pogue J, et al for the ONTARGET investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547\u20131559","DOI":"10.1056\/NEJMoa0801317"},{"key":"169_CR173","first-page":"204","volume-title":"Hypertension, a companion to Braunwald heart disease","author":"A Zanchetti","year":"2012","unstructured":"Zanchetti A (2012) Calcium channel blockers in hypertension. In: Black HR, Elliott WJ (eds) Hypertension, a companion to Braunwald heart disease. Elsevier, Philadelphia, pp 204\u2013218"},{"key":"169_CR174","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","volume":"106","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A et al (2002) On behalf of the ELSA Investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106:2422\u20132427","journal-title":"Circulation"},{"key":"169_CR175","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/HJH.0b013e3282f3e39d","volume":"26","author":"MS Zhou","year":"2008","unstructured":"Zhou MS, Schulman IH, Jaimes EA et al (2008) Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 26:494\u2013500","journal-title":"J Hypertens"},{"key":"169_CR176","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","volume":"48","author":"AJ Zillich","year":"2006","unstructured":"Zillich AJ, Garg J, Basu S et al (2006) Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48:219\u2013224","journal-title":"Hypertension"}],"container-title":["Advances in Experimental Medicine and Biology","Hypertension: from basic research to clinical practice"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2016_169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T18:57:26Z","timestamp":1568573846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2016_169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319442501","9783319442518"],"references-count":177,"URL":"https:\/\/doi.org\/10.1007\/5584_2016_169","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2016]]}}}